The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation
NCT03763721
Bullous Keratopathy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Leuven, Belgium
View Trial DetailsNCT Number: NCT04469933
Aim: Identify predictive factors of good results after primary Descemet's Membrane Endothelial Keratoplasty (DMEK) in Fuchs Endothelial Corneal Dystrophy (FECD).
82 patients (102 eyes) with Fuchs Endothelial Corneal Dystrophy (FECD) underwent DMEK between March 2016 and March 2018 were analyzed. Follow-up time was 12 months. The studied prognostic criteria were: pre-operative Central Corneal Thickness (CCT), CCT's delta between pre and D15 post-operatively, anterior mean keratometry, pre-operative endothelial cell density (ECD) and postoperative ECD at 6 and 12 months, pre-operative visual acuity, donors' and recipients' ages, recipients' sex, rebubbling and triple procedure (DMEK combined with cataract surgery).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Aim: Identify predictive factors of good results after primary Descemet's Membrane Endothelial Keratoplasty (DMEK) in Fuchs Endothelial Corneal Dystrophy (FECD).
A monocentric retrospective observational study was realized at the Regional Hospital Center of Metz-Thionville, Mercy Hospital, Metz, France.
102 eyes of 82 patients with Fuchs Endothelial Corneal Dystrophy (FECD) underwent DMEK between March 2016 and March 2018 were analyzed. Follow-up time was 12 months. The studied prognostic criteria were: pre-operative Central Corneal Thickness (CCT), CCT's delta between pre and D15 post-operatively, anterior mean keratometry, pre-operative endothelial cell density (ECD) and postoperative ECD at 6 and 12 months, pre-operative visual acuity, donors' and recipients' ages, recipients' sex, rebubbling and triple procedure (DMEK combined with cataract surgery). Surgery was considered successful when best spectacle corrected visual acuity (BSCVA) was 0.1 logMar or less (≥0.8) 1 year postoperatively.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: day 1
Pre-operative CCT (μm) measured by an anterior segment optical coherence tomography (AS-OCT; RS-3000; Nidek Co. Ltd, Japan)
Time frame: Months 12
Post-operative CCT (μm) measured by an anterior segment optical coherence tomography (AS-OCT; RS-3000; Nidek Co. Ltd, Japan)
Time frame: day 15
CCT's delta (μm) between pre and D15 post-operatively
Time frame: day 1
anterior mean keratometry (calculated by an auto keratometer Visionix Luneau L67, France)
Time frame: day1
pre-operative ECD (using a non-contact specular microscope CEM-530; Nidek Co. Ltd, Japan)
Time frame: 6 months
post-operative ECD at 6 months (using a non-contact specular microscope CEM-530; Nidek Co. Ltd, Japan)
Time frame: 12 months
post-operative ECD at 12 months (using a non-contact specular microscope CEM-530; Nidek Co. Ltd, Japan)
Time frame: day 1
pre-operative Visual Acuity (using Monoyer chart and converted it to logMar scale)
Time frame: day 1
donors' and recipients' ages
Time frame: day 1
recipients' sex
Time frame: months 6
the rate of rebubbling %(postoperative graft detachment)
Centre Hospitalier Régional Metz-Thionville
Other
Predictive Factors of Good Results After Primary Descemet's Membrane Endothelial Keratoplasty (DMEK): Retrospective Study About 102 Eyes
Acronym: GOODRMEK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03763721
Bullous Keratopathy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Leuven, Belgium
View Trial DetailsNCT07729137
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Diseases
Menlo Park, California, United States
View Trial DetailsNCT06101017
Corneal Disease, Corneal Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT05795699
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Diseases
Los Angeles, California, United States
View Trial Details